Teprotumumab-trbw
Teprotumumab-trbw
Teprotumumab-trbw (pronounced as te pro too' moom ab) is a medication used in the treatment of thyroid eye disease (TED). It is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor 1 receptor (IGF-1R).
Etymology
The name Teprotumumab-trbw is derived from the International Union of Pure and Applied Chemistry (IUPAC) nomenclature. The suffix "-mab" is used for monoclonal antibodies, "t-" for therapeutic, "u-" for human, "pro-" for primate, and "tum-" for neoplastic.
Usage
Teprotumumab-trbw is used for the treatment of adults with thyroid eye disease (TED), a condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge or push forward.
Mechanism of Action
Teprotumumab-trbw works by binding to insulin-like growth factor 1 receptor (IGF-1R) and blocking its activation and signal transduction, which leads to a decrease in the inflammation and other symptoms associated with thyroid eye disease.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Insulin-like growth factor 1 receptor (IGF-1R): A protein found on the surface of human cells. It is a receptor for insulin-like growth factor 1.
- Thyroid eye disease (TED): A condition where the muscles and fatty tissues behind the eye become inflamed.
External links
- Medical encyclopedia article on Teprotumumab-trbw
- Wikipedia's article - Teprotumumab-trbw
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski